Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Small increases or ’blips’ in HIV levels do not signal mutations leading to drug-resistant HIV

16.02.2005


Researchers at Johns Hopkins have concluded that sudden, temporary spikes in the amount of HIV in the body, commonly called "blips," generally do not mean the virus is developing resistance to AIDS drugs and gaining strength in numbers.



"These results should provide relief to hundreds of thousands of HIV-positive patients in the United States currently taking drug therapy, called highly active anti-retroviral therapy, or HAART, and reassure them that their medications have not failed," says senior study author and infectious disease specialist Robert Siliciano, M.D., Ph.D., a professor at The Johns Hopkins University School of Medicine and a Howard Hughes Medical Institute investigator. "Physicians and patients now have a much better idea of when to worry about these blips and when not to worry."

Because HIV mutates very rapidly, physicians and patients have worried that even small, temporary increases in the amount of virus could indicate the virus had mutated to evade anti-viral drugs being taken.


Instead, the Hopkins team has shown that these so-called blips are mathematical artifacts, or variations, that stem from the test used to gauge the amount of virus in the body, a measurement known as viral load.

According to the Hopkins findings, to be published in the Journal of the American Medical Association online Feb. 16, unless the blip is higher than 200 copies per milliliter of blood, or persists upon repeated testing, it does not signal that the virus has mutated, or changed form.

True drug resistance requires changes in therapy which can be very difficult for the patient, says Siliciano. Different combinations of medications can have toxic side effects, such as lipid abnormalities and diabetes, and can be considerably harder to tolerate than the originally prescribed drug cocktail. Today’s anti-HIV drug treatments quickly suppress the virus to nearly undetectable levels, but blips are a frequent problem. Earlier studies suggested that blips occur in 11 percent to 46 percent of patients, while the Hopkins study, which used intensive sampling, found blips in nine-tenths of patients.

To see whether or when blips mean possible mutation, the Hopkins team conducted a detailed genetic analysis of multiple blood samples from 10 HIV-positive patients, taking samples every two to three days for a period of three months between June 2003 and February 2004. All patients had their infection under long-term control, on HAART, and with viral loads of less than 50 copies per milliliter for at least six months. In total, 36 blood samples were taken from each patient.

Statistical analysis of the results showed that blips occurred in nine of the 10 patients with a median viral load of 79 copies per milliliter. The duration of the blips was typically less than three days, and blips were not related to any demographic factors, such as gender or age, nor to any clinical factors, such as illness, vaccination, or differences in antiretroviral drug regimens.

For every blip, the researchers conducted genetic tests on the samples before, during and shortly after the blip, to uncover any mutations in the virus. Measures of viral load were confirmed by using two independent laboratories to test each sample.

No new mutations were found in an analysis of nearly 1,000 viral clones for mutations in HIV’s two key enzymes which are blocked by drug therapy, protease and reverse transcriptase. The authors also found that blips were not, again, detected when blood samples were assayed twice in independent laboratories.

"The lack of any consistency among the tests performed on blood samples confirms that there is no danger from these blips in viral load," says study lead author and infectious disease specialist Richard Nettles, M.D., an assistant professor at Hopkins. "These blips can be attributed to random statistical artifact inherent in measurements of very low amounts of virus."

Siliciano warns that drug resistance is a growing problem in AIDS therapy, as the virus can mutate faster than medical research can develop new drugs. When HIV becomes resistant to one drug, it may also become resistant to other drugs in the same class. With only four classes of HAART drugs - for a total of 20 drugs - the number of available combinations is limited for people who have developed drug resistance.

David March | EurekAlert!
Further information:
http://www.jhmi.edu

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>